The Multi-Modality Platform
for Modern Ophthalmology
Select your specialty
Select your specialty
Opportunity
Glaucoma treatment saves vision. It also systematically destroys the ocular surface. Four distinct mechanisms are working against your patients simultaneously — and the longer they stay on therapy, the worse it gets.
01
The first-line drug you prescribe is also the biggest offender. PGAs don't just lower IOP — they drive obstructive meibomian gland disease at a rate that should alarm every glaucoma specialist.
In a prospective study of medically treated glaucoma patients, 92% of those on PGA monotherapy had MGD, and 95.7% of cases were the obstructive type — thickened, waxy meibum that blocks secretion and starves the tear film of its lipid layer. Patients on non-PGA medications had significantly lower rates at 58.3%, confirming this isn't just an age-related finding. It's drug-specific gland destruction.
Mocan et al., Journal of Glaucoma, 2016
02
Benzalkonium chloride — the most common preservative in glaucoma drops — acts as an accelerant. BAK promotes drug penetration past the conjunctival surface and into the tarsal plate where meibomian glands sit, effectively delivering a toxic payload deeper into tissue that would otherwise resist it.
The damage isn't theoretical and it isn't slow. Statistically significant meibomian gland loss and elevated meibum scores appeared after just 9 months of treatment in both preserved and preservative-free PGA groups. Switching to preservative-free formulations helps, but doesn't eliminate the problem.
Ha et al., PMC, 2019
03
Glaucoma rarely stays on monotherapy forever. As the disease progresses, medications stack. And every additional bottle compounds the ocular surface damage in a clear dose-response relationship.
In a study of over 10,000 glaucoma patients, the odds of developing dry eye disease increased with each medication added: 1.23x with two drugs, 1.63x with three, and 2.60x with four. The patients on the most drops — your most advanced, most at-risk glaucoma patients — are the ones suffering the most surface disease.
Ocular Surface Disease prevalence study, N=10,325 — Singh et al., PMC, 2023
04
Even when patients graduate from drops to surgical intervention, the ocular surface doesn't bounce back on its own. Trabeculectomy is associated with persistent ocular surface signs related to dry eye disease, and while reducing medication burden post-surgery can offer some relief, years of cumulative gland damage don't reverse without direct treatment.
MIGS procedures spare the conjunctiva but still leave patients with whatever meibomian gland atrophy the drops already caused. The glands that were lost during medical therapy stay lost — unless you intervene.
Singh et al., PMC, 2023; Frontiers in Ophthalmology, 2023
Glaucoma therapy is a sustained assault on the meibomian glands. It starts within the first year, worsens with every added medication, and persists even after surgery. The patients sitting in your clinic right now — the ones who tell you their drops burn, the ones who quietly stop using them, the ones whose visual fields look inconsistent because their corneal surface is wrecked — they all have the same underlying problem. And it's treatable.
The Envision Answer
Envision treats the root cause of iatrogenic dry eye with RF and IPL, offering your glaucoma patients a drug-free pathway while generating a new cash-pay revenue stream.
Forma-I
Bipolar RF heats and liquefies clogged meibomian gland secretions, restoring natural oil production and tear film stability.
Lumecca-I
IPL targets lid margin inflammation, ocular rosacea, and Demodex infestations caused by years of chronic topical therapy.
Revenue
$400-700 per session, 4-session protocol. Diversify beyond surgical reimbursement with a new service line your patients need.
Screening Protocol
The single most important diagnostic you can add. Meibography uses infrared imaging to photograph the meibomian glands through the eyelid, producing a direct visualization of gland architecture — including dropout, truncation, and atrophy.
Why it matters for glaucoma: The PGA and BAK damage documented in the literature manifests as structural gland loss that meibography captures clearly. A patient on latanoprost for three years might have zero complaints but show 50-60% gland dropout on imaging. Without meibography, you'd never know until the damage is irreversible.
Why it converts patients: Numbers like osmolarity scores mean nothing to patients. But when you show someone an image of their glands next to a healthy set of glands, and they can see the gaps and atrophy with their own eyes, the conversation changes entirely. Patients who see their own meibography images are far more willing to commit to treatment.
Equipment options:
NIKBUT measures how quickly the tear film destabilizes after a blink without touching the eye or instilling any dye. A projected ring pattern reflects off the tear film and the device records how many seconds until the pattern distorts.
Why it matters: A normal TBUT is 10+ seconds. The PHACO study found 63% of cataract patients had TBUT of 5 seconds or less — and glaucoma patients on chronic drops are likely worse. NIKBUT gives you a quantifiable, repeatable number that tracks treatment progress over time. It's also non-invasive, meaning it doesn't disrupt the tear film the way fluorescein TBUT does, so you get a truer baseline reading.
How it's used clinically: Run NIKBUT at the initial screening, then repeat after the treatment protocol is complete. The before-and-after comparison is powerful both for clinical documentation and for showing the patient their improvement.
Instill fluorescein dye and examine the corneal surface under cobalt blue light. Positive staining reveals superficial punctate keratopathy (SPK) — dead or damaged epithelial cells on the corneal surface that indicate active ocular surface disease.
Why it matters for glaucoma: The chronic inflammatory insult from preserved drops produces corneal surface damage that fluorescein makes visible. This is the same test glaucoma specialists already use during routine exams — the difference is photographing and documenting it systematically rather than just noting "trace SPK" and moving on.
Why it converts patients: Showing a patient a vivid fluorescein photograph of green-staining dots all over their cornea and explaining that those are damaged cells from their drops is a direct, visual conversation. The TopCon SL-S701 is recommended for this because its built-in yellow filter highlights SPK vividly and can demonstrate findings in real time on a monitor.
The treatment happens at a separate visit (or same day if the schedule allows), performed primarily by a technician with the doctor stepping in only for 5 minutes of manual gland expression.
"In glaucoma, we treat early to prevent optic nerve damage. In macular degeneration, we treat early to prevent vision loss. With dry eye, we should do the same — treat early for the best long-term outcomes."
Patient Talking Points
Three conversations that move patients from unaware to committed. Each reframes dry eye treatment as essential to their glaucoma care — not a separate problem.
Talking Point 1
Your glaucoma drops are destroying the oil glands in your eyelids. The preservatives harden the oils your tear film needs, so tears evaporate too fast and your eyes burn. That burning is exactly why patients start skipping drops.
A study of 10,000+ patients found dry eye severity directly predicts medication non-compliance. Treating the gland damage doesn't compete with glaucoma care — it makes your glaucoma care actually work.
Talking Point 2
Meibomian glands don't regenerate. Once gone, they're gone — the same irreversible loss as your optic nerve. On imaging, we can see exactly how much gland structure you still have and how much has been lost.
As few as five functioning lower-lid glands can maintain a healthy tear film. Most long-term drop users still have salvageable tissue — but that window narrows every year without intervention.
Talking Point 3
An unhealthy surface compromises the measurements your entire treatment plan depends on. Irregular corneas make tonometry unreliable — pressure could read artificially high or low, meaning medication and surgical decisions are based on bad data.
If surgery is on the table, the stakes go higher: chronic inflammation is linked to bleb failure, untreated lid disease raises infection risk, and unstable tear film throws off lens calculations. Four sessions over eight weeks gives your surgeon a stable surface to work with.
Implementation
The entire program runs beneath the surgeon — staffed by an OD and technicians, requiring nothing from the MD except a two-sentence referral.
Technician
Screen During Pre-Test
Meibography + NIKBUT added to existing OCT and visual field sequence. Flags candidates before the surgeon walks in.
3-4 min added
Surgeon (MD)
15-Second Warm Referral
"Your glaucoma is stable, but your drops are affecting your oil glands. I want you to see our dry eye team before it gets worse."
15 seconds
OD
Consult & Enroll
Reviews imaging with patient, explains the connection between drops and gland damage, presents treatment plan. The images sell the treatment.
15-20 min
Tech + OD
Treat (x4 Sessions)
Tech performs RF (20 min) and IPL (5-10 min). OD does gland expression (5 min). Every 2-4 weeks.
~30 min/session
OD
Report Back
Post-treatment assessment with before/after imaging. Summary sent to surgeon's chart. Builds confidence, increases referrals.
15 min
The Surgeon
The OD
The Technicians
No marketing spend. 82% of the glaucoma panel has treatable MGD. The pipeline is the existing schedule.
Treatment sessions book between surgical cases or on non-OR days. The lane operates independently.
When the glaucoma surgeon says "see our team," the patient walks down the hall. No records transfer, no new relationship to build.
2 patients/week = 8 treatment appointments created. By month three the calendar fills itself. Patients return every 2-4 weeks, not annually.
No replacement handpieces, cartridges, or disposable tips. Adding an extra session for a stubborn case doesn't eat into margin.
More accurate IOP readings, stable tear films, better biometry for MIGS, lower bleb failure risk, more compliant patients.
The surgeon doesn't build it. Doesn't run it. Doesn't staff it. They refer into it, and their team does the rest. The result: a new six-figure revenue stream without adding a minute to the MD's schedule.
ROI
Treatment packages range from $900 (blepharitis/chalazia) to $3,500 (severe dry eye IPL+RF). The platform generates revenue across dry eye and periorbital aesthetics from a single device. Morpheus8 adds $262.50/series in consumables; Forma-I and Lumecca-I cost nothing per use.
Treatments / month
22
Monthly revenue
$50,900
Months to recoup investment
3.2
Year 1 Profit
$565,290
3-Year Profit
$1,695,870
Based on consistent volume at selected scenario level
Revenue growth by scenario
Monthly revenue by scenario. Each step adds treatments across dry eye, periorbital, and aesthetic categories.
Opportunity
The majority of your cataract patients have undiagnosed ocular surface disease. It's distorting their measurements before surgery and wrecking their comfort after. Every untreated case is a risk to your outcomes, your premium IOL conversion rate, and your reputation.
01
50-70% of patients presenting for cataract surgery have signs of dry eye disease. Most are asymptomatic — they won't tell you about it. The PHACO study found 63% had TBUT of 5 seconds or less, and 77% had meibomian gland dysfunction. This isn't a subset of your patients. It's the majority of your surgical volume.
PHACO Study; Trattler et al., Journal of Cataract & Refractive Surgery
02
An irregular tear film distorts keratometry and topography readings. IOL power calculations built on unstable measurements lead to refractive surprises — the #1 driver of patient dissatisfaction after cataract surgery. Premium IOL patients paying $2,000-4,000 out of pocket expect perfection. A dry ocular surface makes that impossible to deliver consistently.
Epitropoulos et al., Journal of Cataract & Refractive Surgery, 2015
03
Cataract surgery itself damages the ocular surface. The microscope light, corneal incisions, and post-op drop regimens all contribute to worsened dry eye symptoms that peak at 1-3 months post-op — exactly when patients are forming their opinion of their surgical outcome. Unhappy post-op patients don't refer friends. They leave negative reviews.
Cho & Kim, BMC Ophthalmology, 2020
04
Surgeons hesitate to recommend multifocal or EDOF lenses to patients with ocular surface disease because the visual quality complaints will be attributed to the lens. Treating DED pre-operatively expands the pool of patients eligible for premium IOLs — each conversion worth $2,000-4,000 in additional revenue on top of the dry eye treatment fees.
Starr et al., Ophthalmology, 2019
Every cataract surgeon is already performing surgery on dry eyes. The question isn't whether DED affects your outcomes — it does. The question is whether you're going to treat it systematically or keep absorbing the refractive surprises, the post-op complaints, and the premium IOL downgrades.
The Envision Answer
Envision stabilizes the ocular surface pre-operatively so your biometry is accurate, and treats surgery-induced DED post-operatively so your patients are comfortable. One platform across the entire surgical journey.
Forma-I
Bipolar RF restores meibomian gland function and stabilizes the tear film before biometric readings. Stable keratometry means accurate IOL power calculations.
Lumecca-I
IPL calms lid margin inflammation and ocular rosacea before surgery, and accelerates surface recovery post-operatively when patients are most symptomatic.
Revenue
Treating DED expands your multifocal/EDOF-eligible pool. Each premium conversion adds $2,000-4,000 on top of the $500/session dry eye treatment fees.
Screening Protocol
Most practices take biometry at the first surgical evaluation. If anyone notices dry eye, it's after the fact. That sequence is backwards. The ASCRS preoperative OSD algorithm says it clearly: screen first, treat if needed, then measure. Every IOL calculation depends on a corneal surface reflecting light predictably.
Infrared imaging of the meibomian gland architecture. In a cataract patient this serves two purposes: it identifies obstructive MGD that needs treatment, and it predicts whether the tear film will be stable enough to produce repeatable keratometry.
A patient with 50% gland dropout is producing an oil-deficient tear film that evaporates unevenly across the cornea. Every time the keratometer fires, it's measuring a slightly different curvature depending on where the tear film has broken up.
Images go into the chart. The OD reviews them before any surgical measurements are finalized.
This is the test that directly connects to surgical accuracy. NIKBUT measures how many seconds the tear film holds a stable surface after a blink. A healthy film holds 10+ seconds. The PHACO study found 63% of cataract patients were at 5 seconds or less.
Keratometry and topography require light to reflect cleanly. When the tear film breaks up in under 5 seconds, the measurement window is almost nonexistent. That variance translates directly into keratometric error → IOL power error → residual refractive error the patient notices every day.
Clinical threshold: Under 5 seconds — defer measurements until surface is treated. Above 10 seconds — proceed with confidence. In between — clinical judgment, likely treat first.
Positive central corneal staining means the optical zone the patient sees through is damaged — that directly affects visual quality with any IOL, but especially multifocals and EDOF lenses that are already splitting light.
The PHACO study found 77% of cataract patients had positive corneal staining and 50% had central staining — directly over the visual axis. That's half the surgical population with active epithelial damage in the zone that matters most for premium IOL performance.
Photograph it. The image becomes critical when the OD explains why treatment needs to happen before surgery, not after.
The screening identifies which patients need surface optimization before their biometry can be trusted. Defer the IOL Master until the tear film is stable — it's the difference between confident surgical planning and a refractive surprise.
Patient Talking Points
Three conversations that reframe surface treatment as protecting a $4,000 investment — not an optional add-on.
Talking Point 1
Light doesn't hit your premium IOL first — it hits your tear film. When that film breaks up every few seconds, light scatters before it ever reaches the implant. Multifocal lenses split light into multiple focus points and need every photon they can get. A disrupted surface steals contrast, causes fluctuating vision, and produces halos patients blame on the lens.
The lens was never the problem. The surface was. Four sessions stabilize it before measurements and keep it clean after surgery.
Talking Point 2
Your eyes feel fine, but testing shows blocked glands and an unstable tear film. Cataract surgery cuts corneal nerves that regulate tear production, the microscope light dries the surface, and post-op drops contain preservatives that stress it further. Over a third of patients with no dry eye before surgery develop it afterward.
Treating now means faster recovery, fewer symptoms, and a lens that performs as designed from day one.
Talking Point 3
The premium upgrade runs $3,000-5,000 per eye. The treatment protocol is ~$2,000 — roughly 10-15% of that investment. If measurements are off because the tear film was unstable, the lens power might miss. That means residual blur requiring glasses anyway, or a lens exchange — more time, more recovery, more cost.
Four sessions. Thirty minutes each. That's the foundation the entire investment is built on.
Implementation
The surgeon's concern: every week in dry eye treatment is a week not on the surgical schedule. The reality: patients with untreated OSD who get premium IOLs and end up unhappy consume far more time in complaint visits and lens exchanges than 8 weeks of pre-op optimization ever would.
Technician
Screen at Cataract Eval
Meibography + NIKBUT added to IOL Master and topography pre-testing. Flags OSD before surgeon enters.
Week 0
Surgeon
One-Sentence Referral
"Before final measurements, I want our surface team to prepare your eyes. This gives us the most accurate lens calculation."
15 seconds
OD
Consult & Enroll
Reviews imaging, frames treatment as pre-surgical prep. Enrolls patient in 4-session protocol.
Week 1
Tech + OD
4 Treatment Sessions
RF (20 min) + expression (5 min) + IPL (5-10 min). Spaced 2-4 weeks apart based on response.
Weeks 2-14
OD → Surgeon
Clear & Hand Back
OD repeats diagnostics, clears surface for biometry. Final measurements on a stable cornea. Surgery scheduled.
Weeks 15-17
The Surgeon
The OD
The Technicians
$2,000-2,800 per premium IOL patient in treatment fees — generated before surgery happens. Doesn't compete with surgical fees.
Fewer unhappy multifocals, fewer exchanges, fewer "I paid $4K and can't see" conversations. Surface optimization reduces the outcomes that erode your highest-margin service.
37% develop new-onset DED after surgery. Without an internal program, those patients leave for an outside OD. Post-op treatment is a second revenue event you'd otherwise lose.
Surgeons hesitate to recommend multifocals when they've had bad outcomes. Confidence in surface optimization means more upgrade recommendations per surgical slot.
Most practices have a 4-8 week wait to surgery anyway. The protocol runs concurrently — patients aren't waiting longer, they're using the wait productively.
Adding an extra session for a stubborn surface before clearing for surgery costs nothing beyond staff time. Critical when the stakes are a wrong lens power.
The surgeon doesn't build it, run it, or delay their schedule for it. They make one referral, their team handles the rest, and the patient shows up for surgery with the best possible surface to operate on.
ROI
Treatment packages range from $900 (blepharitis/chalazia) to $3,500 (severe dry eye IPL+RF). The platform generates revenue across dry eye and periorbital aesthetics from a single device. Morpheus8 adds $262.50/series in consumables; Forma-I and Lumecca-I cost nothing per use.
Treatments / month
22
Monthly revenue
$50,900
Months to recoup investment
3.2
Year 1 Profit
$565,290
3-Year Profit
$1,695,870
Based on consistent volume at selected scenario level
Revenue growth by scenario
Monthly revenue by scenario. Each step adds treatments across dry eye, periorbital, and aesthetic categories.
Opportunity
You already live in the elective, cash-pay, procedural world. You have the consultation infrastructure, the pricing psychology, and the aesthetic sensibility. What you don't have is a non-surgical option for mild-to-moderate patients, a rapid chalazion pathway, or a medical dry eye program that feeds your aesthetic funnel. Envision fills all three gaps with one platform.
Gap 1
The 55-year-old with early dermatochalasis who doesn't meet surgical criteria. The patient told "come back in a couple years." They leave with nothing — willing to pay, but your only tool was a scalpel and the pathology didn't justify it. So they find a medspa and never come back.
Morpheus8 Prime captures that entire population. 12-pin fractional RF microneedling at 2mm depth, triangular wedge technique for natural brow elevation and lid tightening. 1-3 sessions, $699-999 each, zero downtime vs. 1-3 weeks surgical. These patients become your blepharoplasty patients in 5 years — you're not cannibalizing, you're building the relationship.
Gap 2
The current pathway is broken. Patient gets referred for I&C, waits 3-6 months with a visible lid lesion, applies warm compresses that don't work. The Envision non-surgical protocol eliminates the wait entirely — treatment starts within days.
Forma-I RF softens the obstructed gland, Lumecca-I IPL breaks the inflammatory cycle, then aggressive manual expression while tissue is softened. 3-4 sessions at $300 each, spaced 3-4 days apart. Resolved in under two weeks vs. months of waiting for surgical excision. Maintenance IPL prevents recurrence.
Gap 3
Your patient population is saturated with MGD and evaporative dry eye — the same aging demographic driving your surgical demand. They're already complaining about burning and tearing. They're already getting artificial tears that don't address gland obstruction.
Dry eye becomes the gateway to aesthetics. Patients who come in for MGD treatment notice the RF skin tightening has opened their eyelids and reduced fine lines — now they're receptive to Morpheus8. The clinical sequencing supports it: DED first → Morpheus8 → injectables. A single patient entering through the dry eye door generates $5,000-8,000+ across the full pathway.
Gap 4
A 10-year retrospective of 892 blepharoplasty cases found 26.5% developed dry eye post-operatively. The mechanisms: orbicularis excision reduces blink rate, eyelid incisions transect corneal sensory nerves, and lid position changes increase exposed surface area.
Right now that's managed with artificial tears and unpaid complaint visits. Envision flips it: screen pre-operatively with meibography to identify high-risk surfaces, treat before surgery to reduce post-op severity, and manage post-surgical DED in-house with billable treatment sessions instead of free chair time.
Liebert Pub, 892-case retrospective review; PubMed Central blepharoplasty outcomes
Entry Point
Dry Eye / MGD
Forma-I + Lumecca-I. Medical complaint, not cosmetic. 4 sessions.
$499-699/session
Upsell
Morpheus8 Prime
Patient notices RF tightening. Now receptive to periorbital rejuvenation. 1-3 sessions.
$699-999/session
Enhancement
Injectables
Botox/fillers deployed last. Heat treatments always precede injectables.
Additional revenue
Recurring
Maintenance
DED every 6-12 mo. Morpheus8 every 12-24 mo. Ongoing relationship.
$5K-8K+ lifetime
A single patient entering through the dry eye door can generate $5,000-8,000+ across the full treatment pathway. They entered with a medical complaint — the aesthetic conversion happens organically as they see their own results.
Your typical patient is the highest-value dry eye patient. They're already spending out of pocket on their appearance. They have disposable income. They respond to before-and-after imaging. They refer friends. And unlike a glaucoma patient who returns annually for a covered exam, your patients return voluntarily and pay cash for every visit.
The Envision Answer
Envision combines medical dry eye treatment with periorbital aesthetics — letting you treat the surface disease, rejuvenate the periorbital area, and resolve chalazia all without stepping into the operating room.
Forma-I
Bipolar RF restores meibomian gland function while simultaneously stimulating periorbital collagen remodeling. The medical treatment that doubles as an aesthetic gateway.
Lumecca-I
Treats ocular rosacea, blepharitis, and Demodex while clearing periocular pigmentation, sun damage, and vascular lesions. Medical and cosmetic in one session.
Morpheus8 Prime
Fractional RF microneedling for lid hooding, laxity, and fine lines. Zero downtime. $699-999/session. Captures the pre-surgical patient who would otherwise leave with nothing — or go to a medspa.
Screening & Conversion Pathway
In glaucoma, you screen to find hidden disease. In cataract, you screen to protect a surgical investment. In oculoplastic, you screen to find the starting point of a treatment journey that escalates naturally from medical to aesthetic — with each step generating higher revenue than the last.
Identifies gland obstruction and dropout — but in oculoplastic context it also establishes a medical condition underlying the cosmetic concern. Patient came for hooded lids. Meibography shows 60% gland atrophy. Now you have a medical reason to start with Forma-I and Lumecca-I before discussing aesthetics.
This sequencing isn't arbitrary — the InMode clinical protocol explicitly requires dry eye be controlled before aesthetic treatments begin.
For the blepharoplasty candidate: surgery will make it worse — a patient with TBUT of 3 seconds going in will have a miserable recovery. For the Morpheus8 candidate: establishes baseline surface health you'll track through the entire treatment progression.
Does double duty in oculoplastic: shows the patient their eyes have a real medical problem, not just a cosmetic one, and creates clinical documentation supporting medical necessity of DED treatment before any aesthetic work.
Essential for aesthetic patients. Take standardized photos at initial screening: eyes open, eyes closed, upward gaze, lateral view. Repeat at every milestone — after DED protocol, after each Morpheus8 session. The visual progression sustains patient commitment through multi-phase treatment and generates referrals when they show friends.
By session 3-4 of the DED protocol, patients notice their eyelids look different. The RF energy that melts obstructed meibum at 43°C also stimulates fibroblast activity and collagen production. Tighter skin. Reduced hooding. A more open, lifted appearance. The patient sees it, comments on it — and the Morpheus8 conversation becomes a warm continuation of something already working, not a cold pitch.
Treatment Sequencing
The protocol is explicit: deeper to more superficial, medical before aesthetic, heat before injectables. Each phase follows clinically from the one before it.
Phase 1 — Medical
Control DED
Forma-I + Lumecca-I + expression. 4 sessions. Restores glands, calms inflammation, begins collagen remodeling. Cannot skip this phase.
$2,000-2,800
Phase 2 — Aesthetic
Morpheus8 Prime
Deeper dermal remodeling. Prime tip, 12 pins, 2mm depth. Triangular wedge for brow/lid elevation. 1-3 sessions. Can combine with DED maintenance visits.
$699-2,997
Phase 3 — Refinement
Injectables
Botox + fillers deployed LAST. Heat must precede injectables. Botox near lower lid with laxity can worsen DED by disrupting blink mechanics.
$500-2,000+
Phase 4 — Recurring
Maintenance + Retail
DED every 6-12 mo. Morpheus8 every 12-24 mo. Compresses, omega-3, foamer, SPF, skincare. Multi-year relationship.
$1,200-2,400/yr
Visit 1 — DED Consult
Show meibography, explain gland damage, present DED treatment plan. Don't mention aesthetics. The patient came for a medical reason. Treat it as one.
Sessions 2-3 — Plant the Seed
When the patient notices their lids look different: "That's a secondary benefit of the RF — the same energy heating your glands stimulates collagen in the skin." Don't push. Let them process.
Visit 5 — Post-Treatment
Side-by-side: meibography improvement, NIKBUT improvement, AND external photos. Patient sees healthier eyes AND younger appearance. Now introduce Morpheus8 as the next phase. "We can add it to your maintenance visits."
$5,000-10,000+ per patient before maintenance, with $1,200-2,400 in annual recurring revenue. They entered with a $20 bottle of artificial tears as their treatment plan. They leave as a multi-year aesthetic relationship. At no point did anyone "sell" them anything — the results at each phase created the demand for the next.
Implementation
This isn't ancillary support. This is a fully autonomous program that runs its own patient pipeline, generates revenue across escalating service tiers, and feeds surgical candidates back to the surgeon. The surgeon doesn't support this program — this program supports the surgeon.
01
Three patient types get routed in with one sentence each:
"Not surgical yet" — "There's a non-surgical program we run in-house that can improve skin quality and give you some lift without any downtime."
Lid disease — "We can start treating this in-office this week — no surgery, no wait."
Post-surgical — "The surface takes a hit after lid surgery. My ocular surface team will get your eyes comfortable and help your result settle in faster."
02
The program feeds surgical candidates upstream. The Morpheus8 patient who progresses over 2 years eventually needs blepharoplasty — and they're already in-house. The DED patient screened with early ptosis gets referred for surgical evaluation.
The pipeline builds itself from every patient the surgeon routes in, and returns them when they're ready for the OR.
Entry A
"Not Surgical Yet"
Surgeon refers mild cases. OD screens, starts DED protocol, progresses to Morpheus8 after surface stabilized.
Surgeon referral
Entry B
Chalazion
Immediate non-surgical treatment. Resolved in 2 weeks. OD then screens for underlying MGD → full DED protocol → aesthetics.
$300/session × 3-4
Entry C
Post-Surgical
Bleph/ptosis patient with post-op DED. Surgeon created the problem, program fixes it. Most clinically justified entry point.
Surgeon referral
Entry D
Direct / Marketing
"Dry eye treatment," "non-surgical lid tightening," "chalazion without surgery." Incremental volume the practice never had.
Net new patients
The OD
The Technician
The Coordinator
The oculoplastic surgeon is not on the org chart of this program. They're a referral source and a beneficiary of the patient pipeline. That's it. The program runs beneath them, around them, and feeds patients back to them when they're ready for the OR.
ROI
Treatment packages range from $900 (blepharitis/chalazia) to $3,500 (severe dry eye IPL+RF). The platform generates revenue across dry eye and periorbital aesthetics from a single device. Morpheus8 adds $262.50/series in consumables; Forma-I and Lumecca-I cost nothing per use.
Treatments / month
22
Monthly revenue
$50,900
Months to recoup investment
3.2
Year 1 Profit
$565,290
3-Year Profit
$1,695,870
Based on consistent volume at selected scenario level
Revenue growth by scenario
Monthly revenue by scenario. Each step adds treatments across dry eye, periorbital, and aesthetic categories.